D Elias1, E Benizri, M Pocard, M Ducreux, V Boige, P Lasser. 1. Department of Oncologic Digestive Surgery and Digestive Oncology, Institut Gustave Roussy, Cancer Center Hospital, Rue Camille Desmoulins, 94805 Villejuif Cedex, France. elias@igr.fr
Abstract
AIM: To report our experience of peritoneal carcinomatosis (PC) discovered during abdominal exploration in patients with liver metastases (LM). METHODS: Liver resection plus cytoreductive surgery were combined in 24 patients with LM and moderate PC from colorectal origin treated with a curative intent between January 1993 and November 2003. RESULTS: The mean operative time was 357+/-112 min and median blood loss was 719 ml. One postoperative death occurred and postoperative morbidity was 58%. The mean hospital stay was 21.4+/-4.2 days. Three-year overall and disease-free survival rates were respectively 41.5% (confidence interval [CI]: 23-63) and 23.6% (CI: 11-45). Seven patients are disease-free with a mean follow-up of 27.8 months after their last surgery, 3 having a repeated hepatectomy. Three patients developed a peritoneal recurrence and 13 had recurrence in the liver. The only significant prognostic factor was a number of LMs of less than 3 (p < 0.01). CONCLUSION: A combined treatment of LM plus PC is feasible and is beneficial in selected patients presenting three or fewer metastases.
AIM: To report our experience of peritoneal carcinomatosis (PC) discovered during abdominal exploration in patients with liver metastases (LM). METHODS: Liver resection plus cytoreductive surgery were combined in 24 patients with LM and moderate PC from colorectal origin treated with a curative intent between January 1993 and November 2003. RESULTS: The mean operative time was 357+/-112 min and median blood loss was 719 ml. One postoperative death occurred and postoperative morbidity was 58%. The mean hospital stay was 21.4+/-4.2 days. Three-year overall and disease-free survival rates were respectively 41.5% (confidence interval [CI]: 23-63) and 23.6% (CI: 11-45). Seven patients are disease-free with a mean follow-up of 27.8 months after their last surgery, 3 having a repeated hepatectomy. Three patients developed a peritoneal recurrence and 13 had recurrence in the liver. The only significant prognostic factor was a number of LMs of less than 3 (p < 0.01). CONCLUSION: A combined treatment of LM plus PC is feasible and is beneficial in selected patients presenting three or fewer metastases.
Authors: P Dubé; L Sideris; C Law; L Mack; E Haase; C Giacomantonio; A Govindarajan; M K Krzyzanowska; P Major; Y McConnell; W Temple; R Younan; J A McCart Journal: Curr Oncol Date: 2015-04 Impact factor: 3.677